United Therapeutics Stock Book Value Per Share
| UTH Stock | EUR 280.50 3.20 1.15% |
United Therapeutics fundamentals help investors to digest information that contributes to United Therapeutics' financial success or failures. It also enables traders to predict the movement of United Stock. The fundamental analysis module provides a way to measure United Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to United Therapeutics stock.
United |
United Therapeutics Company Book Value Per Share Analysis
United Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current United Therapeutics Book Value Per Share | 104.20 X |
Most of United Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, United Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
In accordance with the recently published financial statements, the book value per share of United Therapeutics is about 104 times. This is 6229.59% lower than that of the Healthcare sector and 141.91% lower than that of the Biotechnology industry. The book value per share for all Germany stocks is 94.61% higher than that of the company.
Did you try this?
Run Stock Screener Now
Stock ScreenerFind equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
| All Next | Launch Module |
United Fundamentals
| Return On Equity | 0.17 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.38 % | |||
| Operating Margin | 0.51 % | |||
| Current Valuation | 10.24 B | |||
| Shares Outstanding | 46.3 M | |||
| Shares Owned By Insiders | 1.79 % | |||
| Shares Owned By Institutions | 98.21 % | |||
| Price To Earning | 7.31 X | |||
| Price To Book | 2.73 X | |||
| Price To Sales | 6.30 X | |||
| Revenue | 1.94 B | |||
| Gross Profit | 1.78 B | |||
| EBITDA | 1.03 B | |||
| Net Income | 727.3 M | |||
| Cash And Equivalents | 1.79 B | |||
| Cash Per Share | 40.73 X | |||
| Total Debt | 800 M | |||
| Debt To Equity | 41.30 % | |||
| Current Ratio | 4.62 X | |||
| Book Value Per Share | 104.20 X | |||
| Cash Flow From Operations | 802.5 M | |||
| Earnings Per Share | 13.25 X | |||
| Price To Earnings To Growth | 1.00 X | |||
| Target Price | 231.89 | |||
| Number Of Employees | 965 | |||
| Beta | 0.63 | |||
| Market Capitalization | 10.75 B | |||
| Total Asset | 6.04 B | |||
| Z Score | 7.8 | |||
| Net Asset | 6.04 B |
About United Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze United Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of United Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of United Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in United Stock
When determining whether United Therapeutics is a strong investment it is important to analyze United Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact United Therapeutics' future performance. For an informed investment choice regarding United Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in United Stock please use our How to Invest in United Therapeutics guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.